Results 151 to 160 of about 68,648 (313)
Frontiers in PsychiatryIntroductionCompulsive Sexual Behavior Disorder (CSBD) and problematic pornography use (PPU) frequently co-occur with substance use disorders, yet their associations with specific substances in non-clinical populations remain poorly understood.
Wiktoria Stasica, Alicja Anna Binkowska
doaj +1 more source
Addiction, EarlyView.Abstract Background and Aims Cannabis is among the most widely used psychoactive substances globally and is often consumed alongside tobacco. Cannabis use has been associated with impairments in attention, learning, and memory, whereas nicotine can acutely enhance, but chronically impair, certain cognitive functions.
Emese Kroon +5 more
wiley +1 more source
#NoIDVape: A content analysis of illicit vape messaging in young people's information sources
Addiction, EarlyView.Abstract Background and aims In recent years, the increased prevalence of youth vaping in the United Kingdom (UK) may have coincided with a proliferation in the use of ‘illicit’ (unregulated) vapes. Media or educational content about illicit vaping aimed at young people is scarce and poorly understood.
Eleanor Bray +5 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien +15 more
wiley +1 more source
Cannabis consumer responses to the concept of standard THC units
Addiction, EarlyView.Abstract Aims Within a context of considerable cannabis market expansion and product diversification, cannabis consumers must manage their use across a range of potencies and modes of consumption. This study aimed to provide deeper understandings of how cannabis consumers would perceive the introduction of a standard THC (tetrahydrocannabinol) unit ...
Mark Pawson, Mike Vuolo, Brian C. Kelly
wiley +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
The American Journal on Addictions, EarlyView.Abstract Background and Objectives Motives for and contexts of cannabis use (CU) are typically examined as independent characteristics of CU events in ecological momentary assessment (EMA) studies. However, theories posit that some combinations of motives and contexts (e.g., using to cope in a solitary setting) may contribute to heavier substance use ...
Christina Dyar +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr +10 more
wiley +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source